Influence of RANKL inhibition on immune system in the treatment of bone diseases

被引:38
作者
Fouque-Aubert, Anne [1 ]
Chapurlat, Roland [1 ]
机构
[1] Hop Edouard Herriot, Serv Rhumatol, F-69437 Lyon, France
关键词
RANK; RANKL; OPG; osteoclast; B cell; T cell; dendritic cell;
D O I
10.1016/j.jbspin.2007.05.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Receptor activator of nuclear factor-kappa B ligand (RANKL) is essential for osteoclast differentiation, activation and survival. Recently, denosumab, a human monoclonal antibody to RANKL, has been tested in the treatment of osteoporosis. But the interactions between RANKL, receptor activator of nuclear factor-kappa B (RANK) and osteoprotegerin (OPG) are also involved in immune regulations in addition to bone metabolism. So, blocking RANKL could interplay with immune cells and have systemic effects. Here, we review biological data regarding potential consequences of RANKL blocking on the immune system. (c) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:5 / 10
页数:6
相关论文
共 43 条
[1]   A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function [J].
Anderson, DM ;
Maraskovsky, E ;
Billingsley, WL ;
Dougall, WC ;
Tometsko, ME ;
Roux, ER ;
Teepe, MC ;
DuBose, RF ;
Cosman, D ;
Galibert, L .
NATURE, 1997, 390 (6656) :175-179
[2]   TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation [J].
Bachmann, MF ;
Wong, BR ;
Josien, R ;
Steinman, RM ;
Oxenius, A ;
Choi, Y .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (07) :1025-1031
[3]   The effect of a single dose of osteoprotegerin in postmenopausal women [J].
Bekker, PJ ;
Holloway, D ;
Nakanishi, A ;
Arrighi, M ;
Leese, PT ;
Dunstan, CR .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (02) :348-360
[4]  
BEKKER PJ, 2004, J BONE MINER RES, V2005, P2275
[5]   A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases [J].
Body, JJ ;
Greipp, P ;
Coleman, RE ;
Facon, T ;
Geurs, F ;
Fermand, JP ;
Harousseau, JL ;
Lipton, A ;
Mariette, X ;
Williams, CD ;
Nakanishi, A ;
Holloway, D ;
Martin, SW ;
Dunstan, CR ;
Bekker, PJ .
CANCER, 2003, 97 (03) :887-892
[6]   osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [J].
Bucay, N ;
Sarosi, I ;
Dunstan, CR ;
Morony, S ;
Tarpley, J ;
Capparelli, C ;
Scully, S ;
Tan, HL ;
Xu, WL ;
Lacey, DL ;
Boyle, WJ ;
Simonet, WS .
GENES & DEVELOPMENT, 1998, 12 (09) :1260-1268
[7]   RANK is essential for osteoclast and lymph node development [J].
Dougall, WC ;
Glaccum, M ;
Charrier, K ;
Rohrbach, K ;
Brasel, K ;
De Smedt, T ;
Daro, E ;
Smith, J ;
Tometsko, ME ;
Maliszewski, CR ;
Armstrong, A ;
Shen, V ;
Bain, S ;
Cosman, D ;
Anderson, D ;
Morrissey, PJ ;
Peschon, JJ ;
Schuh, J .
GENES & DEVELOPMENT, 1999, 13 (18) :2412-2424
[8]   Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines [J].
Hofbauer, LC ;
Dunstan, CR ;
Spelsberg, TC ;
Riggs, BL ;
Khosla, S .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 250 (03) :776-781
[9]   Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells [J].
Hofbauer, LC ;
Khosla, S ;
Dunstan, CR ;
Lacey, DL ;
Spelsberg, TC ;
Riggs, BL .
ENDOCRINOLOGY, 1999, 140 (09) :4367-4370
[10]   Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand [J].
Hsu, HL ;
Lacey, DL ;
Dunstan, CR ;
Solovyev, I ;
Colombero, A ;
Timms, E ;
Tan, HL ;
Elliott, G ;
Kelley, MJ ;
Sarosi, I ;
Wang, L ;
Xia, XZ ;
Elliott, R ;
Chiu, L ;
Black, T ;
Scully, S ;
Capparelli, C ;
Morony, S ;
Shimamoto, G ;
Bass, MB ;
Boyle, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (07) :3540-3545